RECOVERY OF FETAL CELLS IN MATERNAL BLOOD

母血中胎儿细胞的回收

• 批准号: 2645473
• 负责人: DAVID W SAMMONS
• 金额: $ 36.9万
• 依托单位: BIOSEPARATIONS, INC.
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-05-20 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2645473
• 关键词: amniocentesis; aneuploidy; cell sorting; cell type; chorionic villus sampling; clinical research; diagnosis design /evaluation; electric field; embryo /fetus cell /tissue; erythrocytes; female; flow cytometry; fluorescent in situ hybridization; genetic disorder diagnosis; human middle age (35-64); human pregnant subject; pregnancy circulation; prenatal diagnosis; trisomy

DESCRIPTION (Adapted from applicant's abstract): Fetal cells that enter the mother's blood stream during pregnancy can be recovered by charge flow separation (CFS), a method that obviates the risks associated with amniocentesis and chorionic villus sampling. The long-term objective of this project is development of a commercial system for prenatal screening and diagnosis based on recovery by CFS of fetal nucleated red blood cells (NRBC). The aims of the project are: (I) to increase further the speed and efficiency of CFS, and to decrease disposable costs: (II) to test CFS in the screening of common aneuploidies such as trisomy 13, 18, and 21, and to evaluate the specificity and sensitivity of the screening method; (III) to ascertain the life span of fetal NRBC in the maternal circulation; (IV) to culture CFS-processed fetal NRBC, and to discriminate between female fetal NRBC and maternal NRBC after recovery. For analysis of results, the processed fractions will be tested by FISH and primed in situ labeling (PRINS) for sex- chromosome-complement and the common aneuploidies; the results will be compared with those obtained after conventional cytogenetic analysis. Cultures will be evaluated for paternal DNA sequences and for karyotype. With further development, CFS could enable early diagnosis of a broad spectrum of congenital abnormalities, without risk to fetus or mother. Because the different cell types exhibit characteristic surface charge densities and distinctive mobilities in moving fluids, results with CFS are consistent and reproducible, facilitating experimental design and interpretation. Pretreatment of maternal blood samples with antibody is unnecessary. The method is rapid. The recovered cells are viable and the numbers of fetal NRBC obtained are substantially greater than the numbers obtained after separation by other methods. PROPOSED COMMERCIAL APPLICATION: Not available.

描述（改编自申请人的摘要）：进入的胎儿细胞 母亲怀孕期间的血流可以通过充电来恢复 流动分离（CFS），一种消除相关风险的方法 羊膜穿刺术和绒毛膜绒毛取样。 长期目标 该项目的重点是开发一个产前商业系统 基于胎儿有核红细胞CFS恢复的筛查和诊断 血细胞（NRBC）。 该项目的目标是：（一）提高 进一步提高 CFS 的速度和效率，并减少一次性 成本：(II) 在筛查常见非整倍体中测试 CFS，例如 作为 13、18 和 21 三体，并评估特异性和 筛选方法的灵敏度； （三）寿命的确定 母体循环中胎儿 NRBC 的含量； (IV)培养CFS处理 胎儿 NRBC，并区分女性胎儿 NRBC 和母体 恢复后的NRBC。 为了分析结果，处理后的分数 将通过 FISH 和引物原位标记 (PRINS) 进行性别测试 染色体补体和常见的非整倍体；结果将是 与常规细胞遗传学分析后获得的结果进行比较。 将评估培养物的父本 DNA 序列和核型。 随着进一步发展，CFS 可以实现广泛的早期诊断 一系列先天性异常，对胎儿或母亲没有风险。 因为不同的细胞类型表现出特征表面电荷 移动流体的密度和独特的迁移率，CFS 的结果 一致且可重复，有利于实验设计和 解释。 用抗体预处理母血样本 是不必要的。 该方法快速。 回收的细胞具有活性 并且获得的胎儿 NRBC 数量远大于 通过其他方法分离后得到的数字。 拟议的商业应用：不可用。